TN2011000029A1 - [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase - Google Patents

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase

Info

Publication number
TN2011000029A1
TN2011000029A1 TN2011000029A TN2011000029A TN2011000029A1 TN 2011000029 A1 TN2011000029 A1 TN 2011000029A1 TN 2011000029 A TN2011000029 A TN 2011000029A TN 2011000029 A TN2011000029 A TN 2011000029A TN 2011000029 A1 TN2011000029 A1 TN 2011000029A1
Authority
TN
Tunisia
Prior art keywords
fluoro
inhibitor
methanone
indol
piperidin
Prior art date
Application number
TN2011000029A
Other languages
French (fr)
Inventor
Nakyen Choy
Gregory Bernard Poli
John J Shay Jr
Patrick Wai-Kwok Shum
Adam W Sledeski
Yong Mi Choi-Sledeski
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/054381 external-priority patent/WO2010022196A2/en
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TN2011000029A1 publication Critical patent/TN2011000029A1/en

Links

Abstract

The present invention is directed to an indole benzylamine compound useful as an inhibitor of tryptase. In addition, the present invention is directed to the use of the compound for treating a patient suffering from, or subject to, a physiological condition in need of amelioration by inhibition of tryptase, comprising administering to the patient a therapeutically effective amount of the compound. Furthermore, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula I, and a pharmaceutically acceptable carrier. Formule (I).
TN2011000029A 2009-08-20 2011-01-25 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase TN2011000029A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/054381 WO2010022196A2 (en) 2008-08-22 2009-08-20 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase

Publications (1)

Publication Number Publication Date
TN2011000029A1 true TN2011000029A1 (en) 2012-09-05

Family

ID=55024343

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000029A TN2011000029A1 (en) 2009-08-20 2011-01-25 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase

Country Status (1)

Country Link
TN (1) TN2011000029A1 (en)

Similar Documents

Publication Publication Date Title
UA104148C2 (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
UA83738C2 (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase
MX2011011854A (en) Dihydropyrimidinones for use as bace2 inhibitors.
TN2012000413A1 (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
WO2012079092A3 (en) Testosterone undecanoate compositions
MX2010007714A (en) Fused pyridines active as inhibitors of c-met.
EA201201159A1 (en) DETERATED PYRROPOLYMIDININE COMPOUNDS AS CDK4 / 6 INHIBITORS
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
MX2011011083A (en) Heterocyclic compounds as mek inhibitors.
MX2010014234A (en) Pyrazole compounds 436.
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MY169485A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
UA99787C2 (en) Lactams as beta secretase inhibitors
HK1164721A1 (en) Therapeutic uses of quinazolinedione derivatives
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MX2010003563A (en) C-met protein kinase inhibitors.
MX2008013017A (en) Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor.
WO2010121675A3 (en) Thiazolyl-benzimidazoles
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
MX2010008690A (en) Dual pharmacophores-pde4-muscarinic antagonistics.
MX2011012524A (en) Inhibitors of c-met protein kinase.
MX2010006108A (en) Inhibitors of stearoyl-coa desaturase.
TN2012000242A1 (en) Heterocyclic sulfonamide derivatives
MX2011012522A (en) Substituted pyrazole inhibitors of c-met protein kinase.
UA106082C2 (en) Normal;heading 1;heading 2;heading 3;AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF c-MET PROTIEN KINASE